Summary
14C-radiolabeled (radiocarbon) drug studies are central to defining the disposition of therapeutics in clinical development. Concerns over radiation, however, have dissuaded investigators from conducting these studies as often as their utility may merit. Accelerator mass spectrometry (AMS), originally designed for carbon dating and geochronology, has changed the outlook for in-human radiolabeled testing.
Register to download
Opportunities in low-level radiocarbon microtracing: applications and new technology
You may also be interested in:
Blog
Tips for Managing Stress During COVID-19
With so much uncertainty about the future of our health, economy, and the state of the world, our mental health is put at risk. According to the…
Poster
Retrospective Analysis of the Effects of Protocol Design on Completion Rates in Phase 1 Studies in Subjects with Stable Schizophrenia
Subject attrition from randomized Schizophrenia trials is a significant problem and has been found in meta-analysis to be as high as 76% (Robinowitz…
Case Study
Achieving Challenging Recruitment Goals and Timelines in a Pediatric Type 2 Diabetes Study
Recruiting pediatric patients for type 2 diabetes mellitus (T2DM) studies is extremely challenging. Patients are difficult to identify and often face…